Skip to main content
. Author manuscript; available in PMC: 2015 Feb 17.
Published in final edited form as: Clin Cancer Res. 2013 May 28;19(14):3856–3870. doi: 10.1158/1078-0432.CCR-12-3167

Figure 4.

Figure 4

Experimental validation of transcriptome analysis. A, effects of NXD30001 on cell cycle in ESC-FC1801 cells treated with dimethyl sulfoxide or 1 μmol/L NXD30001. DNA content was measured by flow cytometry. An arrow indicates depletion of cells in S phase, and unstained cells (asterisk) correspond with apoptotic cells. B, DNA synthesis in ESC-FC1801 cells was shown by immunocytochemistry using anti-BrdUrd antibody. C, vascular regression caused by NXD30001, 100 mg/kg/d, 3 times/week for 4 weeks, in ESC-FC1801 and 08031-9 tumors. Immunohistochemical images and the mean number of PECAM-positive blood vessels in the representative sections of the tumors sampled on day 14 (ESC-FC1801) and day 28 (08031-9) were shown. D, upregulation of myelin-specific markers by NXD30001 in NF2-deficient cells. qPCR was conducted on the total RNA isolated from the vehicle or drug-treated tumors (n = 3–8) and cultured cells (n = 3) of FC-1801 and 08031-9. The relative values were expressed against normal sciatic nerve. E, Western blot analysis of myelin-specific proteins in the ESF-FC1801 cells treated with NXD30001. Columns, mean; bars, SD.